Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sapropterin dihydrochloride

- PMLiVE

Charity demands action on cancer drug prices in UK

Breakthrough Breast Cancer wants commitment from all political parties

- PMLiVE

NHS England invests £120m to tackle mental health

Standards to put mental illness on equal footing with physical health issues

- PMLiVE

Cancer Drugs Fund could take on a price assessment role

NHS England consults on a series of significant changes to Fund

- PMLiVE

Janssen backs NHS diabetes challenge

Will provide £200,000 to spread innovation across UK

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

- PMLiVE

England’s Cancer Drugs Fund receives new funding boost

Gains an extra £160m to pay for drugs not recommended by NICE

Sanofi reception

Sanofi and Regeneron pay $67.5m to speed alirocumab review

Buy FDA priority review voucher from BioMarin

- PMLiVE

NHS England takes aim at medicines optimisation

New dashboard to support patients' medicine use has pharma support

Biomarin

EC approves Biomarin rare genetic disorder drug

Vimizim now available to treat Morquio A syndrome

- PMLiVE

McCarthy leaves NHS England

Policy director set for move to the University of Bradford

- PMLiVE

FDA backs BioMarin drug for rare enzyme disorder

Vimizim is first drug approved in US under rare paediatric disease priority review

- PMLiVE

Former Blair adviser to lead NHS England

Simon Stevens to succeed David Nicholson

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links